AstraZeneca PLC (AZN) | Enterprise Value (EV)
Current Enterprise Value (EV)
You have visited 10 password protected pages for free. Others contain data covered by 
.
Sign Up Now to get full access to whole website and cut out all advertisements.
AstraZeneca PLC, current enterprise value calculation
| Current share price (P) | $ |
| No. shares of common stock outstanding | |
| USD $ in millions | |
| Common equity (market value) | |
| Add: Redeemable Preference Shares, £1 each (per books) | |
| Add: Non-controlling interests (per books) | |
| Total equity | |
| Add: Current interest-bearing loans and borrowings (per books) | |
| Add: Non-current interest-bearing loans and borrowings (per books) | |
| Total equity and debt | |
| Less: Other investments | |
| Less: Cash and cash equivalents | |
| Enterprise value (EV) | |
ADVERTISEMENT
Historical Enterprise Value (EV)
You have visited 10 password protected pages for free. Others contain data covered by .
Sign Up Now to get full access to whole website and cut out all advertisements.
AstraZeneca PLC, EV calculation
| Dec 31, 2012 | Dec 31, 2011 | Dec 31, 2010 | Dec 31, 2009 | Dec 31, 2008 | ||
|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | |
|
|
|
|
|
| Share price1, 2 (USD $) | |
|
|
|
|
|
| USD $ in millions | ||||||
| Common equity (market value) | |
|
|
|
|
|
| Add: Redeemable Preference Shares, £1 each (per books) | |
|
|
|
|
|
| Add: Non-controlling interests (per books) | |
|
|
|
|
|
| Total equity | |
|
|
|
|
|
| Add: Current interest-bearing loans and borrowings (per books) | |
|
|
|
|
|
| Add: Non-current interest-bearing loans and borrowings (per books) | |
|
|
|
|
|
| Total equity and debt | |
|
|
|
|
|
| Less: Other investments | |
|
|
|
|
|
| Less: Cash and cash equivalents | |
|
|
|
|
|
| Enterprise value (EV) | |
|
|
|
|
|
2 Close price on the filing date of AstraZeneca PLC's Annual Report.
| Item | Description | The company |
|---|---|---|
| EV | Enterprise value is total company value (the market value of common equity, debt, and preferred equity) minus the value of cash and short-term investments. | AstraZeneca PLC's EV declined from 2010 to 2011 but then increased from 2011 to 2012 not reaching 2010 level. |
ADVERTISEMENT